Carisma Therapeutics (CARM) Short Interest Ratio & Short Volume $0.40 0.00 (-0.07%) Closing price 04:00 PM EasternExtended Trading$0.41 +0.01 (+2.47%) As of 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Carisma Therapeutics Short Interest DataCarisma Therapeutics (CARM) has a short interest of 596,500 shares, representing 2.85% of the float (the number of shares available for trading by the public). This marks a -16.50% decrease in short interest from the previous month. The short interest ratio (days to cover) is 1.7, indicating that it would take 1.7 days of the average trading volume of 347,731 shares to cover all short positions.Current Short Interest596,500 sharesPrevious Short Interest714,400 sharesChange Vs. Previous Month-16.50%Dollar Volume Sold Short$293,478.00Short Interest Ratio1.7 Days to CoverLast Record DateFebruary 15, 2025Outstanding Shares41,750,000 sharesFloat Size20,920,000 sharesShort Percent of Float2.85%Today's Trading Volume188,479 sharesAverage Trading Volume347,731 sharesToday's Volume Vs. Average54% Short Selling Carisma Therapeutics? Sign up to receive the latest short interest report for Carisma Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCARM Short Interest Over TimeCARM Days to Cover Over TimeCARM Percentage of Float Shorted Over Time Carisma Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 2/15/2025596,500 shares $293,478.00 -16.5%2.9%1.7 $0.49 1/31/2025714,400 shares $328,481.12 +63.1%3.3%1.9 $0.46 1/15/2025437,900 shares $195,128.24 -18.6%2.0%1.7 $0.45 12/31/2024537,700 shares $225,188.76 -5.4%2.5%2.1 $0.42 12/15/2024568,400 shares $230,088.32 +2.6%2.6%2.6 $0.40 11/30/2024554,200 shares $473,397.64 -0.8%2.6%3.4 $0.85 11/15/2024558,600 shares $493,355.52 -34.9%2.6%3.8 $0.88 10/31/2024857,500 shares $834,776.25 -18.3%4.0%5.9 $0.97 10/15/20241,050,000 shares $997,290.00 -4.6%4.9%7 $0.95 9/30/20241,100,000 shares $1.08 million -2.7%5.2%5.8 $0.98 Get the Latest News and Ratings for CARM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 9/15/20241,130,000 shares $1.15 million +2.7%5.3%1.4 $1.02 8/31/20241,100,000 shares $1.18 million -1.8%5.3%1.4 $1.07 8/15/20241,120,000 shares $1.18 million +12.5%5.4%1.4 $1.05 7/31/2024995,900 shares $1.07 million -3.3%4.9%1.2 $1.07 7/15/20241,030,000 shares $1.30 million -47.2%5.1%1.3 $1.26 6/30/20241,950,000 shares $2.96 million +42.3%9.7%2.6 $1.52 6/15/20241,370,000 shares $1.56 million -3.5%6.8%7 $1.14 5/31/20241,420,000 shares $1.89 million -9.6%7.0%7.8 $1.33 5/15/20241,570,000 shares $2.20 million -13.7%7.8%9 $1.40 4/30/20241,820,000 shares $2.97 million +10.3%9.4%11 $1.63 4/15/20241,650,000 shares $2.90 million +4.4%8.5%10 $1.76 3/31/20241,580,000 shares $3.59 million +1.9%8.2%10.1 $2.27 3/15/20241,550,000 shares $3.60 million -25.5%8.2%10.6 $2.32 2/29/20242,080,000 shares $5.37 million -13.3%11.1%12.5 $2.58 2/15/20242,400,000 shares $5.50 million -0.8%12.8%13.9 $2.29 1/31/20242,420,000 shares $5.08 million +1.7%12.9%14.4 $2.10 1/15/20242,380,000 shares $6.16 million +10.2%12.8%13.3 $2.59 12/31/20232,160,000 shares $6.33 million -4.0%11.6%10.4 $2.93 12/15/20232,250,000 shares $5.90 million -8.2%12.1%10.3 $2.62 11/30/20232,450,000 shares $5.88 million +2.5%13.2%11.2 $2.40 11/15/20232,390,000 shares $6.12 million +8.1%12.9%11.5 $2.56 10/31/20232,210,000 shares $6.63 million -8.7%11.9%10.8 $3.00 10/15/20232,420,000 shares $8.28 million -2.4%13.1%10.1 $3.42 9/30/20232,480,000 shares $10.49 million -3.9%13.4%11.1 $4.23 9/15/20232,580,000 shares $12.90 million -8.5%13.9%11 $5.00 8/31/20232,820,000 shares $19.51 million -1.7%15.2%9 $6.92 8/15/20232,870,000 shares $19.63 million +3.6%15.5%8.8 $6.84 7/31/20232,770,000 shares $15.37 million +13.1%15.0%8.2 $5.55 7/15/20232,450,000 shares $23.25 million +7.9%13.3%7.8 $9.49 6/30/20232,270,000 shares $19.91 million +246.1%12.3%7.4 $8.77“Amazon Coin” set to outperform Bitcoin (Ad)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career…#1 FREE Crypto for 2025 6/15/2023655,900 shares $4.85 million +25.7%3.6%2.4 $7.40 5/31/2023521,900 shares $2.96 million -18.1%3.2%2.9 $5.67 5/15/2023636,900 shares $3.21 million No Change2.1%3.9 $5.04 CARM Short Interest - Frequently Asked Questions What is Carisma Therapeutics' current short interest? Short interest is the volume of Carisma Therapeutics shares that have been sold short but have not yet been closed out or covered. As of February 15th, traders have sold 596,500 shares of CARM short. 2.85% of Carisma Therapeutics' shares are currently sold short. Learn More on Carisma Therapeutics' current short interest. What is a good short interest ratio for Carisma Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CARM shares currently have a short interest ratio of 2.0. Learn More on Carisma Therapeutics's short interest ratio. Which institutional investors are shorting Carisma Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Carisma Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Carisma Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.85% of Carisma Therapeutics' floating shares are currently sold short. Is Carisma Therapeutics' short interest increasing or decreasing? Carisma Therapeutics saw a decline in short interest during the month of February. As of February 15th, there was short interest totaling 596,500 shares, a decline of 16.5% from the previous total of 714,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Carisma Therapeutics' float size? Carisma Therapeutics currently has issued a total of 41,750,000 shares. Some of Carisma Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Carisma Therapeutics currently has a public float of 20,920,000 shares. How does Carisma Therapeutics' short interest compare to its competitors? 2.85% of Carisma Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Carisma Therapeutics: Protara Therapeutics, Inc. (22.99%), Pyxis Oncology, Inc. (16.28%), Genenta Science S.p.A. (0.02%), Aerovate Therapeutics, Inc. (19.57%), IO Biotech, Inc. (0.05%), Mersana Therapeutics, Inc. (8.40%), Aadi Bioscience, Inc. (4.19%), BeyondSpring Inc. (6.59%), Ikena Oncology, Inc. (1.12%), Clearside Biomedical, Inc. (0.83%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($25.81 billion), iShares 20+ Year Treasury Bond ETF ($10.38 billion), MicroStrategy Incorporated ($7.74 billion), AppLovin Co. ($6.32 billion), Apollo Global Management, Inc. ($5.97 billion), Super Micro Computer, Inc. ($4.89 billion), Charter Communications, Inc. ($4.52 billion), Capital One Financial Co. ($3.94 billion), Schlumberger Limited ($3.19 billion), and Reddit, Inc. ($3.01 billion). View all of the most shorted stocks. What does it mean to sell short Carisma Therapeutics stock? Short selling CARM is an investing strategy that aims to generate trading profit from Carisma Therapeutics as its price is falling. CARM shares are trading down $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Carisma Therapeutics? A short squeeze for Carisma Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CARM, which in turn drives the price of the stock up even further. How often is Carisma Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CARM, twice per month. The most recent reporting period available is February, 15 2025. More Short Interest Resources from MarketBeat Related Companies TARA Short Squeeze PYXS Short Squeeze GNTA Short Squeeze AVTE Short Squeeze IOBT Short Squeeze MRSN Short Squeeze AADI Short Squeeze BYSI Short Squeeze IKNA Short Squeeze CLSD Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CARM) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.